BRCA1 and triple-negative breast carcinoma: With the positive outcome on progression-free survival, olaparib has been further evaluated in Phase III clinical trials in combination with cisplatin/carboplatin with gemcitabine in BRCA1-associated and triple-negative breast cancers [65].